Dupilumab and omalizumab are both effective adjuvant treatments for adults with bullous pemphigoid, though dupilumab may provide better outcomes.

Japan approved rozanolixizumab for self-administration in generalized myasthenia gravis, following the EU's lead, allowing home administration with professional training. The MycarinG study ...

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal ...

The TL1A drug would serve as a companion to Sanofi and partner Regeneron's multibillion-dollar blockbuster Dupixent (dupilumab), which is approved across several indications, including atopic ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Autoimmune bullous diseases are often associated with significant morbidity and some can even cause mortality, if left untreated. Multiple therapies are now available to treat these blistering ...

The FDA granted Priority Review to dupilumab for the treatment of adults with bullous pemphigoid, a chronic, relapsing skin disease characterized by intense itching, blisters, skin reddening ...

A total of 21 studies were included in the systematic review. Ten focused on the use of RTX in combination with IVIG for the treatment of pemphigus and included 85 patients: 47 with pemphigus vulgaris ...

Skin diseases are pathologic conditions that affect the body's surfaces (also called the integument), including skin, hair, nails and associated glands. They can involve all layers of the skin and ...

Neuroendocrine diseases are disorders that affect the interaction between the nervous system and the endocrine system. Examples of diseases of neuroendocrine origin include diabetes insipidus ...

We have updated this service so that members of the same organisation can now collaborate on a joint online response.